Cargando…

Comparison between the Therapeutic Effect of Metformin, Glimepiride and Their Combination as an Add-On Treatment to Insulin Glargine in Uncontrolled Patients with Type 2 Diabetes

AIMS: To compare the commonly prescribed oral anti-diabetic drug (OAD) combinations to use as an add-on therapy with insulin glargine in patients with uncontrolled type 2 diabetes despite submaximal doses of OADs. METHODS: People with inadequately controlled type 2 diabetes (n = 99) were randomly as...

Descripción completa

Detalles Bibliográficos
Autores principales:	Park, Cheol-Young, Kang, Jun Goo, Chon, Suk, Noh, Junghyun, Oh, Seung Joon, Lee, Chang Beom, Park, Sung Woo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3948620/ https://www.ncbi.nlm.nih.gov/pubmed/24614911 http://dx.doi.org/10.1371/journal.pone.0087799

Ejemplares similares

Sitagliptin 100 mg vs glimepiride 1–3 mg as an add-on to insulin and metformin in type 2 diabetes (SWIM)
por: Kesavadev, Jothydev, et al.
Publicado: (2017)

Effect of hydroxychloroquine on beta cell function, insulin resistance, and inflammatory markers in type 2 diabetes patients uncontrolled on glimepiride and metformin therapy
por: Rajput, Rajesh, et al.
Publicado: (2023)

Efficacy and safety of dapagliflozin or dapagliflozin plus saxagliptin versus glimepiride as add‐on to metformin in patients with type 2 diabetes
por: Müller‐Wieland, Dirk, et al.
Publicado: (2018)

Effects of Evogliptin as Add on in Type 2 Diabetes (T2DM) Subjects Inadequately Controlled With Metformin and Glimepiride Combination
por: Guha, Shaibal
Publicado: (2021)

Comparison of Vildagliptin-Metformin and Glimepiride-Metformin Treatments in Type 2 Diabetic Patients
por: Jeon, Hyun Jeong, et al.
Publicado: (2011)

Twice-daily insulin glargine for patients with uncontrolled type 2 diabetes mellitus
por: Eledrisi, Mohsen, et al.
Publicado: (2018)

Cost effectiveness of vildagliptin versus glimepiride as add-on treatment to metformin for the treatment of diabetes mellitus type 2 patients in Greece
por: Kousoulakou, Hara, et al.
Publicado: (2017)

Comparison of the Efficacy of Glimepiride, Metformin, and Rosiglitazone Monotherapy in Korean Drug-Naïve Type 2 Diabetic Patients: The Practical Evidence of Antidiabetic Monotherapy Study
por: Yoon, Kun Ho, et al.
Publicado: (2011)

Comparison of Combined Tofogliflozin and Glargine, Tofogliflozin Added to Insulin, and Insulin Dose-Increase Therapy in Uncontrolled Type 2 Diabetes
por: Suzuki, Katsunori, et al.
Publicado: (2016)

The Anti-Breast Cancer Effect and Mechanism of Glimepiride-Metformin Adduct
por: Long, Liangyuan, et al.
Publicado: (2020)

Superior efficacy of insulin degludec/liraglutide versus insulin glargine U100 as add‐on to sodium‐glucose co‐transporter‐2 inhibitor therapy: A randomized clinical trial in people with uncontrolled type 2 diabetes
por: Philis‐Tsimikas, Athena, et al.
Publicado: (2019)

Sitagliptin/Metformin Versus Insulin Glargine Combined With Metformin in Obese Subjects With Newly Diagnosed Type 2 Diabetes
por: Ji, Ming, et al.
Publicado: (2016)

Comparative Studies of Palmatine with Metformin and Glimepiride on the Modulation of Insulin Dependent Signaling Pathway In Vitro, In Vivo & Ex Vivo
por: Nwabueze, Okechukwu Patrick, et al.
Publicado: (2022)

The Cost-Effectiveness of Alogliptin Versus Sulfonylurea as Add-on Therapy to Metformin in Patients with Uncontrolled Type 2 Diabetes Mellitus
por: Gordon, Jason, et al.
Publicado: (2016)

Glimepiride and Metformin Combinations in Diabetes Comorbidities and Complications: Real-World Evidence
por: Sahay, Rakesh Kumar, et al.
Publicado: (2020)

Pharmacodynamic and pharmacokinetic interaction of losartan with glimepiride-metformin combination in rats and rabbits
por: Nagaraju, Beere, et al.
Publicado: (2021)

Insulin glargine overdose
por: Doğan, Fatma Sarı, et al.
Publicado: (2012)

Efficacy and Safety of Self-Titration Algorithms of Insulin Glargine 300 units/mL in Individuals with Uncontrolled Type 2 Diabetes Mellitus (The Korean TITRATION Study): A Randomized Controlled Trial
por: Bae, Jae Hyun, et al.
Publicado: (2022)

Clinical Evidence and Practice-Based Guidelines on the Utility of Basal Insulin Combined Oral Therapy (Metformin and Glimepiride) in the Current Era
por: Shrivastava, Abhishek, et al.
Publicado: (2023)

An analysis of early insulin glargine added to metformin with or without sulfonylurea: impact on glycaemic control and hypoglycaemia
por: Fonseca, V, et al.
Publicado: (2011)

Effects of Vildagliptin Add-on Insulin Therapy on Nocturnal Glycemic Variations in Uncontrolled Type 2 Diabetes
por: Li, Feng-fei, et al.
Publicado: (2017)

Duration of action of two insulin glargine products, LY2963016 insulin glargine and Lantus insulin glargine, in subjects with type 1 diabetes mellitus
por: Linnebjerg, Helle, et al.
Publicado: (2016)

Impacts of early insulin treatment vs glimepiride in diabetic patients with background metformin therapy: A nationwide retrospective cohort study
por: Yen, Fu-Shun, et al.
Publicado: (2021)

Comparison of Safety and Efficacy of Glimepiride-Metformin and Vildagliptin- Metformin Treatment in Newly Diagnosed Type 2 Diabetic Patients
por: Kumar, Surendra
Publicado: (2021)

Insulin glargine and the risk of cancer
por: Ahmed, FA
Publicado: (2010)

Propensity‐score‐matched comparative analyses of simultaneously administered fixed‐ratio insulin glargine 100 U and lixisenatide (iGlarLixi) vs sequential administration of insulin glargine and lixisenatide in uncontrolled type 2 diabetes
por: Rosenstock, Julio, et al.
Publicado: (2018)

Efficacy of Gemigliptin Add-on to Dapagliflozin and Metformin in Type 2 Diabetes Patients: A Randomized, Double-Blind, Placebo-Controlled Study (SOLUTION)
por: Lee, Byung Wan, et al.
Publicado: (2023)

Comparison of Oral Antidiabetic Drugs as Add-On Treatments in Patients with Type 2 Diabetes Uncontrolled on Metformin: A Network Meta-Analysis
por: Qian, Dan, et al.
Publicado: (2018)

Assessment of the Drug Interaction Potential of Ertugliflozin With Sitagliptin, Metformin, Glimepiride, or Simvastatin in Healthy Subjects
por: Dawra, Vikas Kumar, et al.
Publicado: (2018)

A Glimepiride-Metformin Multidrug Crystal: Synthesis, Crystal Structure Analysis, and Physicochemical Properties
por: Bian, Xufei, et al.
Publicado: (2019)

Effect of exenatide QW or placebo, both added to titrated insulin glargine, in uncontrolled type 2 diabetes: The DURATION‐7 randomized study
por: Guja, Cristian, et al.
Publicado: (2018)

Metformin add-on continuous subcutaneous insulin infusion on precise insulin doses in patients with type 2 diabetes
por: Li, Feng-fei, et al.
Publicado: (2018)

Effectiveness and Safety of Adding Basal Insulin Glargine in Patients with Type 2 Diabetes Mellitus Exhibiting Inadequate Response to Metformin and DPP-4 Inhibitors with or without Sulfonylurea
por: Kang, Yu Mi, et al.
Publicado: (2019)

Immunogenicity and Efficacy of Insulin Glargine Biosimilar Ezelin versus Originator Insulin Glargine in Patients with Type 2 Diabetes
por: Tarigan, Tri Juli Edi, et al.
Publicado: (2021)

Real-World Observational Study of Glimepiride and Metformin Fixed-Dose Combination Along With Insulin in the Management of Type 2 Diabetes Mellitus: Indian Experience
por: Prasanna Kumar, KM, et al.
Publicado: (2021)

Deduction of the operable design space of RP-HPLC technique for the simultaneous estimation of metformin, pioglitazone, and glimepiride
por: Marie, Aya A., et al.
Publicado: (2023)

Bioequivalence Comparison of Two Formulations of Fixed-Dose Combination Glimepiride/Metformin (2/500 mg)Tablets in Healthy Volunteers
por: Jung, Sang-hoon, et al.
Publicado: (2014)

Effects of insulin glargine versus metformin on glycemic variability, microvascular and beta-cell function in early type 2 diabetes
por: Pistrosch, F., et al.
Publicado: (2013)

Investigational new insulin glargine 300 U/ml has the same metabolism as insulin glargine 100 U/ml
por: Steinstraesser, A, et al.
Publicado: (2014)

Effect of once‐weekly semaglutide versus thrice‐daily insulin aspart, both as add‐on to metformin and optimized insulin glargine treatment in participants with type 2 diabetes (SUSTAIN 11): A randomized, open‐label, multinational, phase 3b trial
por: Kellerer, Monika, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_cif2b65gu1qi2ol94qm7nf5d84